Home Newsfeeds CEI’s Subsidiary Provides Update on Patent for Medical Waste Treatment Technology

News

CEI’s Subsidiary Provides Update on Patent for Medical Waste Treatment Technology

https://www.accesswire.com/708864/CEIs-SubsidiaryProvides-Update-on-Patent-for-Medical-Waste-Treatment-Technology

byBenzinga Newsdesk

July 18, 2022

1 minute read

https://www.accesswire.com/708864/CEIs-SubsidiaryProvides-Update-on-Patent-for-Medical-Waste-Treatment-Technology

Fusion Pharmaceuticals To Present Interim Data From Phase 1 Trial Of FPI-1434 in Patients With Solid Tumors Expressing IGF-1R

By Happy Mohamed

June 26, 8:05 AM

Preliminary Clinical Data with Cold/Hot Dosing Regimen Demonstrate Potential to Improve Therapeutic Index and Safety Profile Company Prioritizing Cold/Hot Dosing Regimen in Phase 1 Trial; Cohort 2 in this Arm is

FUSN

MasterCraft Boat Hldgs Q2 Adj EPS $1.20 Beats $1.01 Estimate, Sales $159.20M Beat $150.66M Estimate

By Benzinga Newsdesk

February 8, 8:31 AM

MasterCraft Boat Hldgs (NASDAQ:MCFT) reported quarterly earnings of $1.20 per share which beat the analyst consensus estimate of $1.01 by 18.81 percent. This is a 31.87 percent increase over earnings of $0.91 per share

MCFT

TerrAscend Reports Record Q4 Revenue Increase Of 4% Sequentially & Full Year 2022 Highlights

By Maureen Meehan

March 16, 7:21 PM

TerrAscend Corp. (OTCQX: TRSSF) reported its financial results Thursday afternoon for the fourth quarter and full year ended December 31, 2022. Q4 financial highlights include:

TRSSF

Piper Sandler Maintains Overweight on New York Community, Lowers Price Target to $11

By Benzinga Newsdesk

December 5, 7:46 AM

Piper Sandler analyst Mark Fitzgibbon maintains New York Community (NYSE:NYCB) with a Overweight and lowers the price target from $14 to $11.

NYCB

CEI’s Subsidiary Provides Update on Patent for Medical Waste Treatment Technology

https://www.accesswire.com/708864/CEIs-SubsidiaryProvides-Update-on-Patent-for-Medical-Waste-Treatment-Technology

Related Posts

Fusion Pharmaceuticals To Present Interim Data From Phase 1 Trial Of FPI-1434 in Patients With Solid Tumors Expressing IGF-1R

MasterCraft Boat Hldgs Q2 Adj EPS $1.20 Beats $1.01 Estimate, Sales $159.20M Beat $150.66M Estimate

TerrAscend Reports Record Q4 Revenue Increase Of 4% Sequentially & Full Year 2022 Highlights

Piper Sandler Maintains Overweight on New York Community, Lowers Price Target to $11